Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non‐Hodgkin lymphoma mostly pretreated with rituximab: A multicenter phase II study
暂无分享,去创建一个
Y. Ohashi | S. Nawano | M. Ogura | S. Mori | M. Kurosawa | T. Kinoshita | K. Tobinai | N. Uike | K. Itoh | H. Nagai | T. Igarashi | A. Hiraoka